Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies, Federal Facilities, and Certain Other Entities

Health and Human Services Department; Food and Drug Administration · 2018

Read Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies, Federal Facilities, and Certain Other Entities by Health and Human Services Department; Food and Drug Administration (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2018-15095.txt.

Description

Notice published in the Federal Register on 2018-07-16 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 32882-32883] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2018-15095] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2016-D-4318] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry.

Catalog record

CREATORHealth and Human Services Department; Food and Drug Administration
YEAR2018
COLLECTIONLAW
FORMATTXT
FILE SIZE11 KB
VERSION1.0
LICENSEPublic Domain
RIGHTSPUBLIC DOMAIN
SOURCEFederal Register

Source: https://www.federalregister.gov/documents/2018/07/16/2018-15095/agency-information-collection-activities-submission-for-office-of-management-and-budget-review

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies, Federal Facilities, and Certain Other Entities Citation: us:fr:2018-15095 Creator: Health and Human Services Department; Food and Drug Administration Year: 2018 Source-URL: https://www.federalregister.gov/documents/2018/07/16/2018-15095/agency-information-collection-activities-submission-for-office-of-management-and-budget-review Context: Notice published in the Federal Register on 2018-07-16 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 32882-32883] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2018-15095] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2016-D-4318] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Compounding and Repackaging of Radiopharmaceuticals by State- Licensed Nuclear Pharmacies, Federal Facilities, and Certain Other Entities AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by August 15, 2018. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to [email protected]. All comments should be identified with the OMB control number 0910-NEW and title ``Guidance for Industry on Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies, Federal Facilities, and Certain Other Entities.'' Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, [email protected]. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Guidance for Industry on Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies, Federal Facilities, and Certain Other Entities OMB Control Number--NEW This information collection supports the Agency guidance document entitled ``Guidance for Industry on Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies, Federal Facilities, and Certain Other Entities.'' Under current law, radiopharmaceuticals that are compounded by entities that are not registered with FDA as outsourcing facilities, and radiopharmaceuticals that are repackaged, are subject to all applicable provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) related to drug production. Because Congress explicitly excluded radiopharmaceuticals from section 503A of the FD&C Act (21 U.S.C. 353a) (see section 503A(d)(2)), compounded radiopharmaceuticals are not eligible for the exemptions under section 503A from section 505 of the FD&C Act (21 U.S.C. 355) (concerning new drug approval requirements), section 502(f)(1) of the FD&C Act (21 U.S.C. 352(f)(1)) (concerning labeling with adequate directions for use), and section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)) (concerning current good manufacturing practice requirements). In addition, the FD&C Act does not provide an exemption for repackaged radiopharmaceuticals. FDA developed this guidance document to describe the conditions under which the Agency generally does not intend to take action for violations of sections 505, 502(f)(1), and 501(a)(2)(B) of the FD&C Act when a State-licensed nuclear pharmacy, Federal facility, or other facility that is not an outsourcing facility and that holds a radioactive materials license for medical use issued by the Nuclear Regulatory Commission or by an Agreement State compounds or repackages radiopharmaceuticals for human use. One of the guidance document's conditions is that the compounded radiopharmaceutical is not essentially a copy of an approved radiopharmaceutical. If a compounder intends to rely on a determination from a prescriber that there is a change between the compounded radiopharmaceutical and the comparable approved radiopharmaceutical that produces a clinical difference for an identified individual patient, either the prescribing practitioner or the compounder documents the determination on the prescription or order in writing. This documentation reflects a conversation with the prescribing practitioner, and the compounder maintains records of the prescription or order documenting this determination. In the Federal Register of December 29, 2016 (81 FR 96011), FDA published a notice of availability for the draft guidance, including a 60-day notice soliciting public comment on the information collection recommendations. Several comments were received and are discussed below; however, none of the comments suggested we revise the burden estimate from our 60-day notice. (Comment 1) One commenter said documentation of a minor deviation from an approved radiopharmaceutical should remain at the facility that performed the minor deviation. (Response 1) The documentation condition (i.e., documentation of a prescriber's determination that there is a change that produces a clinical difference between the compounded radiopharmaceutical and the comparable FDA-approved radiopharmaceutical for an identified individual patient) does not apply to compounding that consists only of minor deviations as defined in the guidance document (i.e., a change from the approved labeling in radioactivity, volume, or the step-by- step procedures made when compounding the radiopharmaceutical from an FDA-approved drug product in a patient-ready dose). The documentation condition applies to compounding a radiopharmaceutical that involves manipulation other than minor deviations. (Comment 2) One commenter supports the requirement for notating clinical differences, particularly for documenting both the change to the radiopharmaceutical and the reason that the change is important for the patient. (Response 2) FDA concurs with this commenter's views about the importance of the documentation. [[Page 32883]] FDA's guidance document states that the documentation condition would be met if the prescription for the compounded radiopharmaceutical makes clear that the prescriber identified the relevant change between the approved radiopharmaceutical and the compounded radiopharmaceutical and the clinical difference that the change produces for the patient. (Comment 3) One commenter recommended that the guidance document require written documentation when a commercially manufactured radiopharmaceutical is compounded for a patient because the radiopharmaceutical is unavailable due to a drug shortage. (Response 3) The guidance document explains that FDA does not consider a compounded radiopharmaceutical to be essentially a copy of a marketed FDA-approved radiopharmaceutical if the FDA-approved radiopharmaceutical is on FDA's drug shortage list (see section 506E of the FD&C Act (21 U.S.C. 356e)) at the time of compounding and distribution. FDA maintains a database for drug shortages. If the Agency identifies a compounded radiopharmaceutical that has the characteristics of a drug that is ``essentially a copy,'' FDA intends to review its database to determine whether there was a shortage of the approved radiopharmaceutical at the time of compounding and distribution. FDA estimates the burden of this collection of information as follows: Table 1--Estimated Annual Third-Party Disclosure Burden 1 -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of Type of reporting Number of disclosures Total annual Average burden per disclosure Total hours respondents per respondent disclosures -------------------------------------------------------------------------------------------------------------------------------------------------------- Consultation between the compounder and 10 25 250 0.05 (3 minutes).......................... 12.5 prescriber and the notation on the prescription or order documenting the prescriber's determination of clinical difference. -------------------------------------------------------------------------------------------------------------------------------------------------------- 1 There are no capital costs or operating and maintenance costs associated with this collection of information. The total estimated third-party disclosure burden for the guidance document is shown above. We estimate that a total of approximately 10 compounders annually (``No. of

Read the complete text